- Ukwelashwa
- Ubufakazi
- I-Neuroblastoma
- Isimila Esiqinile
- Ubufakazi
- I-TILS
- Ukwelashwa Kwamaseli e-NK
- I-Myasthenia Gravis (MG)
- I-Acute Lymphoblastic Leukemia (B-ALL)
- I-Systemic Lupus Erythematosus (SLE)
- I-Acute Lymphoblastic Leukemia (T-ALL)
- I-Non-Hodgkin Lymphoma (NHL)
- I-Multiple Myeloma (MM)
- I-Diffuse Large B-cell Lymphom
- I-B-lymphocytic Leukemia
- I-Myeloma
I-Acute Lymphoblastic Leukemia (T-ALL)-07
Intombazane yaseMiao ithola ukuphulukiswa okuphelele ngemva kokwelashwa nge-CAR-T ngemuva kokubuyela emuva kokufakelwa.
U-Amei, umfundi we-postgraduate waseHunan waseMiao, wayeshicilele amaphepha amabili e-SCI. Ngo-Ephreli 2, 2020, wangeniswa esibhedlela sesifundazwe ngenxa yomkhuhlane ophindaphindayo. Ukuhlolwa komnkantsha kwathola ukuthi une-acute lymphoblastic leukemia (T-ALL). Ngemva kwezifundo eziningi ze-chemotherapy esibhedlela sangaphandle, umnkantsha wakhe wahlala usesimweni esingcono. NgoNovemba 2, 2020, wafakelwa i-allogeneic hematopoietic stem cell esibhedlela sethu (umfowabo nodadewabo, i-HLA 7/10 match). Ngemva kokufakelwa, amangqamuzana afakwa ngempumelelo, futhi ukuhlolwa komnkantsha okulandelayo kwabonisa ukuphulukiswa okuqhubekayo.
Ngomhlaka-16 Juni 2021 (izinyanga ezingu-7 ngemuva kokufakelwa), ukuhlolwa okuvamile kwembula ukubuyela emuva kwe-leukemia yakhe. Ukwelashwa ngamakhemikhali okwalandela kwehlulekile ukulawula lesi sifo, futhi waba nokutheleleka kwe-pneumonia kanye ne-herpes virus, kanye nezilonda zomlomo ezibuhlungu ezenza kwaba nzima ukugwinya. Wangeniswa ewadini lesibili lomnyango we-hematology futhi wabhaliswa esivivinyweni somtholampilo se-CD7 CAR-T.
Ithimba lezokwelapha linikeze ukwelashwa okusebenzayo kokulwa nokutheleleka, ukuqeda ubuhlungu, kanye nokumpontshelwa igazi nama-platelet amaningi. Ngenxa yomthwalo omkhulu wesimila (ukuqhuma okungu-80% emnkantsheni wamathambo kanye nokuqhuma okungu-97% egazini elingaphandle), kwakungenakwenzeka ukuqoqa amangqamuzana akhe. Ama-lymphocyte egazi angaphandle avela kumnikeli (umfowabo) aqoqwa futhi athunyelwa enkampanini ye-biotech yokukhulisa amangqamuzana e-CAR-T.
Ngomhlaka-10 Agasti 2021, amaseli e-CD7 CAR-T athathwe ngabanikeli aphinde afakwa. Ngemva kokufakwa kabusha, amaseli e-CAR-T anda afinyelela ku-54.64% egazini elingaphandle, enomkhuhlane kuphela futhi engenayo i-significant cytokine release syndrome (CRS) noma isifo se-graft-versus-host (GVHD). Ukuhlolwa komnkantsha ngosuku lwe-16 ngemuva kokufakwa kabusha kwabonisa ukuphulukiswa okuphelele, ngamaseli e-CAR-T angu-54.13% emnkantsha. Ngosuku lwama-36, umnkantsha waqhubeka nokubonisa ukuphulukiswa okuqhubekayo. Njengamanje, isimo sakhe sengqondo, ubuthongo, kanye nesifiso sokudla kuhle, futhi uyalulama kahle.
incazelo2
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

